298 related articles for article (PubMed ID: 28676644)
1. Blocking autophagy improves the anti-tumor activity of afatinib in lung adenocarcinoma with activating EGFR mutations in vitro and in vivo.
Hu X; Shi S; Wang H; Yu X; Wang Q; Jiang S; Ju D; Ye L; Feng M
Sci Rep; 2017 Jul; 7(1):4559. PubMed ID: 28676644
[TBL] [Abstract][Full Text] [Related]
2. Distinct Afatinib Resistance Mechanisms Identified in Lung Adenocarcinoma Harboring an EGFR Mutation.
Yamaoka T; Ohmori T; Ohba M; Arata S; Murata Y; Kusumoto S; Ando K; Ishida H; Ohnishi T; Sasaki Y
Mol Cancer Res; 2017 Jul; 15(7):915-928. PubMed ID: 28289161
[TBL] [Abstract][Full Text] [Related]
3. Glycolysis inhibition sensitizes non-small cell lung cancer with T790M mutation to irreversible EGFR inhibitors via translational suppression of Mcl-1 by AMPK activation.
Kim SM; Yun MR; Hong YK; Solca F; Kim JH; Kim HJ; Cho BC
Mol Cancer Ther; 2013 Oct; 12(10):2145-56. PubMed ID: 23883584
[TBL] [Abstract][Full Text] [Related]
4. APE1 stimulates EGFR-TKI resistance by activating Akt signaling through a redox-dependent mechanism in lung adenocarcinoma.
Lu GS; Li M; Xu CX; Wang D
Cell Death Dis; 2018 Oct; 9(11):1111. PubMed ID: 30382076
[TBL] [Abstract][Full Text] [Related]
5. EGFR tyrosine kinase inhibitors activate autophagy as a cytoprotective response in human lung cancer cells.
Han W; Pan H; Chen Y; Sun J; Wang Y; Li J; Ge W; Feng L; Lin X; Wang X; Wang X; Jin H
PLoS One; 2011; 6(6):e18691. PubMed ID: 21655094
[TBL] [Abstract][Full Text] [Related]
6. Small Molecule T315 Promotes Casitas B-Lineage Lymphoma-Dependent Degradation of Epidermal Growth Factor Receptor via Y1045 Autophosphorylation.
Huang KY; Kao SH; Wang WL; Chen CY; Hsiao TH; Salunke SB; Chen JJ; Su KY; Yang SC; Hong TM; Chen CS; Yang PC
Am J Respir Crit Care Med; 2016 Apr; 193(7):753-66. PubMed ID: 26583948
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Combined Use of Everolimus and Second-Generation Pan-EGRF Inhibitors in
da Silva-Oliveira RJ; Gomes INF; da Silva LS; Lengert AVH; Laus AC; Melendez ME; Munari CC; Cury FP; Longato GB; Reis RM
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887120
[TBL] [Abstract][Full Text] [Related]
8. [Tumor microenvironment elicits primary resistance to afatinib through HGF secretion].
Kang XH; Wang LF; Cao F; Fan FT; Xu ZY
Zhonghua Zhong Liu Za Zhi; 2013 Oct; 35(10):732-6. PubMed ID: 24378092
[TBL] [Abstract][Full Text] [Related]
9. [The CK2 inhibitor quninalizarin enhances the anti-proliferative effect of icotinib on EGFR-TKIs-resistant cell lines and its underlying mechanisms].
Zhou Y; Zhang S; Li K; Li QW; Zhou FZ; Li ZY; Ma H; Dong XR; Liu L; Wu G; Meng R
Zhonghua Zhong Liu Za Zhi; 2016 Feb; 38(2):100-4. PubMed ID: 26899328
[TBL] [Abstract][Full Text] [Related]
10. The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer.
Yonesaka K; Kudo K; Nishida S; Takahama T; Iwasa T; Yoshida T; Tanaka K; Takeda M; Kaneda H; Okamoto I; Nishio K; Nakagawa K
Oncotarget; 2015 Oct; 6(32):33602-11. PubMed ID: 26418897
[TBL] [Abstract][Full Text] [Related]
11. Inhibitory Effects of HangAmDan-B1 (HAD-B1) Combined With Afatinib on H1975 Lung Cancer Cell-Bearing Mice.
Kang HJ; Kim J; Cho SH; Park SJ; Yoo HS; Kang IC
Integr Cancer Ther; 2019; 18():1534735419830765. PubMed ID: 30866688
[TBL] [Abstract][Full Text] [Related]
12. Auranofin Enhances Ibrutinib's Anticancer Activity in EGFR-Mutant Lung Adenocarcinoma.
Hu J; Zhang H; Cao M; Wang L; Wu S; Fang B
Mol Cancer Ther; 2018 Oct; 17(10):2156-2163. PubMed ID: 30065099
[TBL] [Abstract][Full Text] [Related]
13. Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib.
Yamaoka T; Ohba M; Matsunaga Y; Tsurutani J; Ohmori T
J Vis Exp; 2019 Jun; (148):. PubMed ID: 31305510
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of combined icotinib and pemetrexed in EGFR mutant lung adenocarcinoma cell line xenografts.
Cui J; Zhang Y; Su D; Li T; Li Y
Thorac Cancer; 2018 Sep; 9(9):1156-1165. PubMed ID: 30047610
[TBL] [Abstract][Full Text] [Related]
15. Secreted Phosphoprotein 1 (SPP1) Contributes to Second-Generation EGFR Tyrosine Kinase Inhibitor Resistance in Non-Small Cell Lung Cancer.
Wang X; Zhang F; Yang X; Xue M; Li X; Gao Y; Liu L
Oncol Res; 2019 Aug; 27(8):871-877. PubMed ID: 30832751
[TBL] [Abstract][Full Text] [Related]
16. EPHA2 blockade reverses acquired resistance to afatinib induced by EPHA2-mediated MAPK pathway activation in gastric cancer cells and avatar mice.
Chen Z; Liu Z; Zhang M; Huang W; Li Z; Wang S; Zhang C; Dong B; Gao J; Shen L
Int J Cancer; 2019 Nov; 145(9):2440-2449. PubMed ID: 30957241
[TBL] [Abstract][Full Text] [Related]
17. Targeting YAP-p62 signaling axis suppresses the EGFR-TKI-resistant lung adenocarcinoma.
Park HS; Lee DH; Kang DH; Yeo MK; Bae G; Lee D; Yoo G; Kim JO; Moon E; Huh YH; Lee SH; Jo EK; Cho SY; Lee JE; Chung C
Cancer Med; 2021 Feb; 10(4):1405-1417. PubMed ID: 33486901
[TBL] [Abstract][Full Text] [Related]
18. Pseudolaric acid B suppresses NSCLC progression through the ROS/AMPK/mTOR/autophagy signalling pathway.
Luo D; He F; Liu J; Dong X; Fang M; Liang Y; Chen M; Gui X; Wang W; Zeng L; Fan X; Wu Q
Biomed Pharmacother; 2024 Jun; 175():116614. PubMed ID: 38670047
[TBL] [Abstract][Full Text] [Related]
19. Aspirin boosts the synergistic effect of EGFR/p53 inhibitors on lung cancer cells by regulating AKT/mTOR and p53 pathways.
Liu Z; Cui L; Wang J; Zhao W; Teng Y
Cell Biochem Funct; 2024 Jan; 42(1):e3902. PubMed ID: 38100146
[TBL] [Abstract][Full Text] [Related]
20. Primary Resistance to Afatinib in a Patient with Lung Adenocarcinoma Harboring Uncommon EGFR Mutations: S768I and V769L.
Niogret J; Coudert B; Boidot R
J Thorac Oncol; 2018 Jul; 13(7):e113. PubMed ID: 29935845
[No Abstract] [Full Text] [Related]
[Next] [New Search]